Equine Sports Council

Controlled Medications Library

ESC MEDICATION CLASSIFICATIONClass A - Therapeutic

ESC Medication Library · Revision 2

← Medication library · Compare sanctioning bodies

Medication Facts

Performance enhancing
conditionally
Total hours to clear
Not recorded
Frequently used
N/A
ESC ID
GUAIFE-0440
Trade names
Mucinex, Gecolate
Drug type
Centrally Acting Muscle Relaxer
Plasma half-life · hours
3 hours
Equine dosing
50 to 100 mg/kg IV administered as a 5% or 10% solution, typically combined with other agents for short-duration total intravenous anesthesia (TIVA)
Cmax · peak plasma concentration
323 ng/mL
Tmax · time to peak plasma concentration
15 min
ESC concentration guidance
12 ng/mL
Primary withdrawal · hours
48
Washout withdrawal · hours
0
ESC control type
A1 - Generally Controlled - Therapeutic
Medication report required
Generally not required, however understand exceptions.

Uses & side effects

Used in nebulizers to reduce mucus, also used as a muscle relaxant during equine surgury

Product-specific side effects await source review.

Drug interactions

Guaifenesin for Horses
Developed in collaboration with
Barbara Forney, VMD
Last reviewed: 07/13/2022
Commonly prescribed for: Anesthetic Protocols

Species: Horses

Therapeutic Class: Centrally Acting Muscle Relaxant

Basic Information
Guaifenesin is a centrally acting muscle relaxant that is used as a part of many anesthetic protocols in the horse. Its mechanism of action is not precisely known but the relaxation of skeletal muscles, mild analgesic and mild sedative properties allows for lower doses of other sedatives and anesthetic agents. Guaifenesin is used for induction before inhalation anesthesia, during inhalation anesthesia and with total intravenous anesthesia (TIVA) for short procedures. Guaifenesin has minimal effects on diaphragmatic function and produces relatively little respiratory depression at normal doses. It is used primarily in horses although it has been studied and is used in other domestic species.

Guaifenesin within a Triple Drip combination also is administered with inhalant anesthesia as a means of reducing the total amount of inhalant used in a given case. This combination of intravenous and inhalant anesthesia is referred to as "balanced anesthesia." Balanced anesthesia has the advantages of less cardiovascular depression, diminished need for additional drugs to support hemodynamics and improved recoveries.

Guaifenesin Side Effects
Guaifenesin may cause a mild decrease in blood pressure and an increase in heart rate.
There are conflicting reports regarding hemolysis and reactions of the vascular endothelium with higher concentration solutions of guaifenesin.
Remember to tell your veterinarian about any medications, vitamins, supplements, or herbal therapies that you are giving to your pet.

Precautions
ARCI Class 4 drug.
Guaifenesin has been shown to cross the placenta. Neonatal levels immediately after delivery were about 30% of the level in the mare. TIVA with Triple Drip has been used successfully in field situations for dystocia. Appropriate ventilation and respiratory support for the foal may be necessary.
Donkeys and to a lesser extent mules may be more sensitive to guaifenesin. Mules are reported to be intermediate between horses and donkeys.
Perivascular administration will cause tissue reaction. Guaifenesin should be administered using an intravenous catheter.
Drug Interactions
Anticholinesterase drugs such as physostigmine are contraindicated. (Plumb 2005)

Overdose
Guaifenesin is relatively safe. The margin of safety is reported to be three times the normal dose and cardiovascular side effects are rare. Signs of overdose include apneustic breathing, nystagmus, hypotension and increased muscle rigidity. Although there is no specific antidote, Guaifenesin has a relatively short half-life (60 to 85 minutes) (Plumb 2005). Supportive treatment should be instituted while the drug is being cleared.

Popular Guaifenesin Dosage Forms
Wedgewood provides medication options that help ensure accurate dosing, especially for hard to medicate pets. Click below for a complete list of Wedgewood’s dosing forms and strengths.

Contraindications

Sanctioning-body comparison

Plasma only. Compare published competition guidance for this medication. ESC guidance remains in Medication Facts above. A dosing guideline, withdrawal recommendation and laboratory detection threshold are different measures.

Sources reviewed September 23, 2026. “Not verified” means a gap in this comparison, not zero tolerance or permission. Doses describe the cited rules; your veterinarian must determine treatment and withdrawal.

Published guidance by organization
OrganizationPublished dose & routePlasma concentrationWithdrawal / timingControl / penalty class
AQHA Show HorsesShow rules · 2026 handbook
Conditions & sources

An unverified entry is not permission to use this medication. Consult the linked current rules.

Reviewed 2026-09-23

Not verified for this medication.Not verified for this medication.Not verified for this medication.Medication-specific control not yet verified.
APHA Paint Show HorsesShow rules · 2026 Rule Book
Conditions & sources

An unverified entry is not permission to use this medication. Consult the linked current rules.

Reviewed 2026-09-23

Not verified for this medication.Not verified for this medication.Not verified for this medication.Medication-specific control not yet verified.
ARCI Model RulesRacing model · Rules 15 / UCG 20.0 / CTMS 4.2.1
Conditions & sources

ARCI model comparison only; no state-specific rule is substituted. Schedule timing is tied to its stated regimen and is not a clearance guarantee.

CTMS 4.2.1; UCG 20.0 PDF p. 32

Reviewed 2026-09-23

2 g twice daily for 5 doses; route not specified in schedule12 ng/mL48 h withdrawal guidelineDrug Class 4 · Penalty Class C. Controlled therapeutic schedule; classification shown below.
USEFNational Therapeutic Substance Provisions · 2026 + July amendment
Conditions & sources

An unverified entry is not permission to use this medication. Consult the linked current rules.

Reviewed 2026-09-23

Not verified for this medication.Not verified for this medication.Not verified for this medication.Medication-specific control not yet verified.